75 related articles for article (PubMed ID: 21370050)
21. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation.
Kreisberg JF; Yonemoto W; Greene WC
J Exp Med; 2006 Apr; 203(4):865-70. PubMed ID: 16606671
[TBL] [Abstract][Full Text] [Related]
22. APOBEC3G and HIV-1: strike and counterstrike.
Soros VB; Greene WC
Curr HIV/AIDS Rep; 2007 Feb; 4(1):3-9. PubMed ID: 17338854
[TBL] [Abstract][Full Text] [Related]
23. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
He Z; Zhang W; Chen G; Xu R; Yu XF
J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
[TBL] [Abstract][Full Text] [Related]
24. APOBEC3G and HIV-1: strike and counterstrike.
Soros VB; Greene WC
Curr Infect Dis Rep; 2006 Jun; 8(4):317-23. PubMed ID: 16822376
[TBL] [Abstract][Full Text] [Related]
25. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells.
Pido-Lopez J; Whittall T; Wang Y; Bergmeier LA; Babaahmady K; Singh M; Lehner T
J Immunol; 2007 Feb; 178(3):1671-9. PubMed ID: 17237417
[TBL] [Abstract][Full Text] [Related]
26. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.
Xu H; Chertova E; Chen J; Ott DE; Roser JD; Hu WS; Pathak VK
Virology; 2007 Apr; 360(2):247-56. PubMed ID: 17126871
[TBL] [Abstract][Full Text] [Related]
27. Status of APOBEC3G/F in cells and progeny virions modulated by Vif determines HIV-1 infectivity.
Yamashita T; Nomaguchi M; Miyake A; Uchiyama T; Adachi A
Microbes Infect; 2010 Feb; 12(2):166-71. PubMed ID: 19944180
[TBL] [Abstract][Full Text] [Related]
28. The HIV-1 accessory protein Vpr induces the degradation of the anti-HIV-1 agent APOBEC3G through a VprBP-mediated proteasomal pathway.
Zhou D; Wang Y; Tokunaga K; Huang F; Sun B; Yang R
Virus Res; 2015 Jan; 195():25-34. PubMed ID: 25200749
[TBL] [Abstract][Full Text] [Related]
29. APOBEC3G Interacts with ssDNA by Two Modes: AFM Studies.
Shlyakhtenko LS; Dutta S; Banga J; Li M; Harris RS; Lyubchenko YL
Sci Rep; 2015 Oct; 5():15648. PubMed ID: 26503602
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 subtype variability in Vif derived from molecular clones affects APOBEC3G-mediated host restriction.
Lisovsky I; Schader SM; Sloan RD; Oliveira M; Coutsinos D; Bernard NF; Wainberg MA
Intervirology; 2013; 56(4):258-64. PubMed ID: 23689841
[TBL] [Abstract][Full Text] [Related]
31. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif.
Shirakawa K; Takaori-Kondo A; Yokoyama M; Izumi T; Matsui M; Io K; Sato T; Sato H; Uchiyama T
Nat Struct Mol Biol; 2008 Nov; 15(11):1184-91. PubMed ID: 18836454
[TBL] [Abstract][Full Text] [Related]
32. Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes.
McDougall WM; Okany C; Smith HC
J Biol Chem; 2011 Sep; 286(35):30655-30661. PubMed ID: 21737457
[TBL] [Abstract][Full Text] [Related]
33. Induction of heat-shock protein 70 by prostaglandin A₁ inhibits HIV-1 Vif-mediated degradation of APOBEC3G.
Sugiyama R; Abe M; Nishitsuji H; Murakami Y; Takeuchi H; Takaku H
Antiviral Res; 2013 Sep; 99(3):307-11. PubMed ID: 23831493
[TBL] [Abstract][Full Text] [Related]
34. Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells.
Stalder R; Blanchet F; Mangeat B; Piguet V
J Leukoc Biol; 2010 Dec; 88(6):1251-8. PubMed ID: 20807705
[TBL] [Abstract][Full Text] [Related]
35. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
[TBL] [Abstract][Full Text] [Related]
36. ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.
Miyakawa K; Matsunaga S; Kanou K; Matsuzawa A; Morishita R; Kudoh A; Shindo K; Yokoyama M; Sato H; Kimura H; Tamura T; Yamamoto N; Ichijo H; Takaori-Kondo A; Ryo A
Nat Commun; 2015 Apr; 6():6945. PubMed ID: 25901786
[TBL] [Abstract][Full Text] [Related]
37. Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection.
Thangavelu PU; Gupta V; Dixit NM
Virology; 2014 Jan; 449():224-8. PubMed ID: 24418556
[TBL] [Abstract][Full Text] [Related]
38. IFN-α induces APOBEC3G, F, and A in immature dendritic cells and limits HIV-1 spread to CD4+ T cells.
Mohanram V; Sköld AE; Bächle SM; Pathak SK; Spetz AL
J Immunol; 2013 Apr; 190(7):3346-53. PubMed ID: 23427247
[TBL] [Abstract][Full Text] [Related]
39. Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.
Monajemi M; Woodworth CF; Benkaroun J; Grant M; Larijani M
Retrovirology; 2012 Apr; 9():35. PubMed ID: 22546055
[TBL] [Abstract][Full Text] [Related]
40. Ubiquitin-fusion as a strategy to modulate protein half-life: A3G antiviral activity revisited.
Cadima-Couto I; Freitas-Vieira A; Nowarski R; Britan-Rosich E; Kotler M; Goncalves J
Virology; 2009 Oct; 393(2):286-94. PubMed ID: 19717177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
